Literature DB >> 17877921

The role of CETP inhibition in dyslipidemia.

Karim El Harchaoui1, Wim A van der Steeg, Erik S G Stroes, John J P Kastelein.   

Abstract

Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17877921     DOI： 10.1007/s11883-007-0008-5

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  51 in total

1.  Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.

Authors:  Radjesh J Bisoendial; G Kees Hovingh; Karim El Harchaoui; Johannes H M Levels; Sotirios Tsimikas; Kewei Pu; Aeilko E Zwinderman; Jan Albert Kuivenhoven; John J P Kastelein; Erik S G Stroes
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-09       Impact factor: 8.311

2.  Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins.

Authors:  M Passarelli; S Catanozi; E R Nakandakare; J C Rocha; R E Morton; A F Shimabukuro; E C Quintão
Journal:  Diabetologia       Date:  1997-09       Impact factor: 10.122

3.  The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.

Authors:  Andrea Kassai; László Illyés; Hossein Z Mirdamadi; Ildiko Seres; Tímea Kalmár; Mária Audikovszky; György Paragh
Journal:  Clin Biochem       Date:  2006-06-09       Impact factor: 3.281

4.  Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia.

Authors:  J D Bagdade; M C Ritter; P V Subbaiah
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway.

Authors:  Fumihiko Matsuura; Nan Wang; Wengen Chen; Xian-Cheng Jiang; Alan R Tall
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.

Authors:  N A Le; W Innis-Whitehouse; X Li; R Bakker-Arkema; D Black; W V Brown
Journal:  Metabolism       Date:  2000-02       Impact factor: 8.694

7.  Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.

Authors:  S Matthijs Boekholdt; Jan-Albert Kuivenhoven; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Robert Luben; Sheila A Bingham; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

8.  Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.

Authors:  C J Mann; F T Yen; A M Grant; B E Bihain
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

9.  Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men.

Authors:  R P Dullaart; K Hoogenberg; B D Dikkeschei; A van Tol
Journal:  Arterioscler Thromb       Date:  1994-10

10.  Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.

Authors:  P N Durrington; M I Mackness; D Bhatnagar; K Julier; H Prais; S Arrol; J Morgan; G N Wood
Journal:  Atherosclerosis       Date:  1998-05       Impact factor: 5.162
View more
  6 in total

1.  Will CETP inhibition survive the demise of torcetrapib?

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

2.  The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623).

Authors:  Natalie L Trevaskis; Claire L McEvoy; Michelle P McIntosh; Glenn A Edwards; Ravi M Shanker; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2010-03-11       Impact factor: 4.200

3.  The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles.

Authors:  Natalie L Trevaskis; Ravi M Shanker; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2010-07-16       Impact factor: 4.200

4.  Subcutaneous Adipocyte Lipolysis Contributes to Circulating Lipid Levels.

Authors:  Mikael Rydén; Peter Arner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-29       Impact factor: 8.311

Review 5.  Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis.

Authors:  Tianhua Zhang; Jin Chen; Xiaoyu Tang; Qin Luo; Danyan Xu; Bilian Yu
Journal:  Lipids Health Dis       Date:  2019-12-16       Impact factor: 3.876

6.  Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults.

Authors:  Ye-Seul Kim; Hee-Taik Kang; Joungyoun Kim; Sang-Jun Shin
Journal:  Cardiovasc Diabetol       Date:  2021-09-09       Impact factor: 9.951
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.